Immutep (ADR) (IMMP)
Develops LAG-3 immunotherapies for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Develops efti, an LAG-3/MHC Class II agonist, alongside IMP761 for autoimmune disease. Its former pivotal TACTI-004 study in first-line non-small-cell lung cancer was discontinued after an interim futility analysis.
Develops LAG-3-related immunotherapies for cancer and autoimmune disease. Its main molecule, eftilagimod alfa (efti), is a soluble LAG-3/MHC Class II agonist studied in non-small-cell lung cancer, head-and-neck squamous-cell carcinoma, and metastatic breast cancer.
TACTI-004 was the global Phase III study of efti in first-line advanced or metastatic non-small-cell lung cancer. It paired efti with pembrolizumab and chemotherapy, but was discontinued after an interim futility analysis; the company announced an orderly wind-down of the study.
IMP761, a LAG-3 agonist antibody, is in first-in-human testing for autoimmune disease. The clinically pre-commercial business depends on clinical progress, regulatory review, and collaborations; the company said it would reassess capital-allocation priorities after its TACTI-004 operational and data analyses.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Jun 17, 2026 | Maxim Group | Upgrade | Hold | Buy |
| Mar 13, 2026 | Baird | Downgrade | Outperform | Neutral |
| Mar 13, 2026 | Citizens | Downgrade | Market Outperform | Market Perform |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $49.5M · Total debt $752.5K · Total assets $59.8M · Shareholders' equity $44.2M
- Revenue
- $7.6M
- Operating income
- −$28.4M
- Net income
- −$25.1M
Reported in AUD, converted at the latest exchange rate
No dividends on record.
| Institutions28 holders · as of Mar 31, 2026 | 1.77% | 2.61M ADS | |
| Insiders8 holders · as of Apr 16, 2026 | 4.43% | 6.53M ADS | |
| Otherremainder | 93.80% | 138.24M ADS |
147.37M ADS (1 ADS = 6 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Jun 2022 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Marc VoigtInsiderdirector, officer: See Remarks | 1.68% | 14.88M ordinary | Form 4filed Apr 13, 2026 ↗ |
Frederic Joseph Daniel TriebelInsiderdirector | 1.28% | 11.35M ordinary | Form 4filed Apr 1, 2026 ↗ |
BlackRock, Inc.Institution | 0.55% | 810,926 ADS | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 0.51% | 748,811 ADS | 13Fas of Mar 31, 2026 |
Pete A. MeyersInsiderdirector | 0.46% | 4.05M ordinary | Form 4filed Apr 7, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- Bristol-Myers Squibb
Anti-LAG-3/PD-1 regimen in recruiting first-line NSCLC Phase III.
- Regeneron
LAG-3/PD-1 development with fianlimab and cemiplimab.
- AstraZeneca (ADR)
Approved PD-L1/CTLA-4/chemotherapy option in metastatic NSCLC.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immutep (ADR) | $0.3717 | −2.93% | $56.4M | — | — | 5.0 | +702.3% |
| Bristol-Myers Squibb | $67.38 | −0.40% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Median | 21.1 | 14.1 | 4.1 | +6.4% |